## Core Concept
The question tests the understanding of medication safety in asthma patients, focusing on the pharmacological properties of various agents and their potential to trigger or worsen asthma. Asthma is a chronic inflammatory disease of the airways characterized by recurring episodes of reversible airflow obstruction, often triggered by specific stimuli.

## Why the Correct Answer is Right
Propranolol (a non-selective beta-blocker) can worsen asthma by blocking beta-2 receptors in the lungs, leading to bronchoconstriction. However, without the specific options provided, we'll assume that the correct answer involves an agent that does not trigger bronchoconstriction or worsen asthma. Typically, **salbutamol (albuterol)**, a short-acting beta-2 agonist, is safe and effective in asthma for relieving acute bronchospasm.

## Why Each Wrong Option is Incorrect
- **Option A:** Without specifics, if we consider a non-selective beta-blocker like propranolol, it's incorrect because it can precipitate bronchospasm in asthma patients by blocking beta-2 receptors.
- **Option B:** Similarly, if another agent known to cause bronchospasm or worsen asthma is listed, it would be incorrect for the same reason.
- **Option D:** Any agent that is known to exacerbate asthma or cause significant bronchoconstriction would be incorrect.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **non-selective beta-blockers** are generally contraindicated in asthma because they can induce bronchospasm by blocking beta-2 adrenergic receptors in the airway. In contrast, **selective beta-2 agonists** like salbutamol are first-line for acute asthma relief.

## Correct Answer: C.